Form 4: Carrano Dominic Gabriel reports acquisition/exercise transactions in MANE

Rhea-AI Filing Summary

Carrano Dominic Gabriel reported acquisition or exercise transactions in a Form 4 filing for MANE. The filing lists transactions totaling 148,011 shares. Following the reported transactions, holdings were 148,011 shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Carrano Dominic Gabriel

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	148,011	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 148,011 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Carrano Dominic Gabriel

(Last) (First) (Middle)

C/O VERADERMICS, INCORPORATED

470 JAMES ST.

(Street)

NEW HAVEN CT 06513

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Veradermics, Inc [ MANE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)	X	Other (specify below)
	Chief Financial Officer		Treasurer

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$17	02/03/2026		A		148,011		(1)	02/03/2036	Common Stock	148,011	$0	148,011	D

Explanation of Responses:

1. The option vests as to 25% of the underlying shares of the Issuer's common stock, par value $0.00001 per share, on February 3, 2027, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal monthly installments over 36 months thereafter, subject to continued service.

Remarks:

	/s/ Michael Greco, Attorney-in-Fact	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Veradermics (MANE) disclose in this Form 4 for its CFO?

Veradermics disclosed a stock option grant to its CFO. Dominic Gabriel Carrano received an option to buy 148,011 shares of common stock at a $17 exercise price, expiring February 3, 2036, with vesting over four years tied to his continued service.

How many Veradermics (MANE) shares are covered by the CFO’s stock option?

The stock option covers 148,011 shares of common stock. Dominic Gabriel Carrano was granted a “Stock Option (Right to Buy)” for 148,011 underlying shares at a $17 exercise price, reflected as 148,011 derivative securities beneficially owned directly after the transaction.

What is the exercise price and term of the Veradermics (MANE) CFO option grant?

The option has a $17 exercise price and a 10-year term. The grant dated February 3, 2026 allows purchase of common stock at $17 per share and expires on February 3, 2036, giving a long-dated equity incentive period.

What is the vesting schedule for Dominic Gabriel Carrano’s Veradermics (MANE) option?

The option vests over four years with an initial cliff. Twenty-five percent vests on February 3, 2027, one year after the vesting commencement date. The remaining shares vest in equal monthly installments over the next 36 months, conditioned on continued service.

Is the Veradermics (MANE) CFO’s stock option held directly or indirectly?

The option is reported as directly owned. The Form 4 lists 148,011 derivative securities beneficially owned following the transaction with ownership form marked as “D” for direct, with no nature of indirect beneficial ownership specified.

What transaction code is used for the Veradermics (MANE) CFO option grant?

The transaction is coded as an “A” grant or award. The Form 4 classifies the February 3, 2026 stock option as a derivative acquisition, using transaction code A for a grant, award, or other acquisition, rather than an open-market purchase or sale.